Title : Preclinical and clinical experience with dasatinib in Philadelphia chromosome-negative leukemias and myeloid disorders.

Pub. Date : 2009 May

PMID : 19013641






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Dasatinib is a tyrosine kinase inhibitor with activity against BCR-ABL, platelet-derived growth factor receptors (PDGFRs), c- KIT, fibroblast growth factor receptors (FGFRs), SRC family kinases (SFKs), and EPHA receptors, all of which have been implicated in the pathogenesis of Ph- leukemias and myeloid disorders. Dasatinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens